# Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

> **NCT04291729** · PHASE4 · COMPLETED · sponsor: **The Ninth Hospital of Nanchang** · enrollment: 11 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ganovo+ritonavir+/-Interferon nebulization

## Key facts

- **NCT ID:** NCT04291729
- **Lead sponsor:** The Ninth Hospital of Nanchang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291729, "Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04291729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*